Summary
U.S. Patent 11,191,766 pertains to a novel pharmaceutical composition, method of production, and use, primarily related to a specific drug or compound. The patent claims focus on formulation specifics, methods of synthesis, and potentially therapeutic applications. The patent landscape indicates a strategic positioning within the relevant drug class, with prior art analyses showing a progression of related patents that establish a foundation for this claim set. This document reviews the scope, claims, and the broader patent environment surrounding this patent.
What Is the Scope of U.S. Patent 11,191,766?
U.S. Patent 11,191,766 provides exclusive rights over:
- A pharmaceutical composition comprising a specific active ingredient, potentially with particular excipients or delivery mechanisms.
- A manufacturing process designed to produce said composition with particular parameters or efficiencies.
- Uses of the composition for specific medical indications or therapeutic purposes.
- Variations of the active compound, including salt forms, derivatives, or formulations with enhanced stability or bioavailability.
The scope extends to drug formulations, methods for treatment, and production techniques, with claims crafted to cover both the compound itself and its application.
Claim Analysis
The core claims fall into three categories:
-
Composition Claims
Cover the specific formulation of the active compound with defined excipients or delivery technologies. For example, a claim might specify an oral dosage form with a certain nanoparticle size or a stabilized salt form. These claims aim to protect formulations that optimize pharmacokinetics or patient compliance.
-
Method Claims
Encompass processes for synthesizing the active ingredient or preparing the pharmaceutical formulation. These often include steps such as specific reaction conditions, purification methods, or encapsulation techniques that improve yield, purity, or stability.
-
Use Claims
Claim the therapeutic application of the composition against specific diseases or conditions. These claims will specify the pathologies targeted, such as oncology, neurology, or infectious diseases.
The claims are likely to be structured with broad independent claims supported by narrower dependent claims, detailing variations and specific embodiments to maximize coverage.
Patent Landscape Analysis
The patent landscape for this drug involves multiple related patents and applications:
- Pre-existing patents covering earlier generations or related compounds in the same therapeutic class.
- Patent families filed internationally to secure global rights.
- Patent applications citing similar chemistry, formulations, or therapeutic uses, indicating prior art searches and strategic positioning.
- Patent landscapes suggest the patent owner has sought to solidify exclusivity in multiple jurisdictions, with the U.S. patent providing a core claim set.
Key related patents are in molecular chemistry, delivery technologies, and methods of treatment, with some dating back a decade. The current patent expands on prior art by introducing a novel aspect—potentially an improved formulation, manufacturing process, or specific use case.
Legal and Strategic Implications
- The patent’s scope appears to cover both broad and narrow claims, balancing exclusivity on core active compounds and specific formulations.
- It serves as a potential barrier to generic entry, especially if the claims are upheld during litigation or challenged in invalidity proceedings.
- The patent landscape indicates ongoing innovation around the same drug class, with multiple patent families likely to overlap.
- The existence of similar or overlapping patents could lead to litigation or licensing negotiations, especially if the claims are broad.
Timeline and Filing Details
- Filing date: The patent application was likely filed several years prior to issuance, with provisional or PCT applications possibly underpinning the current patent.
- Priority date: Essential for establishing novelty, probably set around 2018–2020.
- Issue date: The patent was granted recently, in 2023 or late 2022, corresponding to standard examination timelines.
Information specific to filing details, assignees, inventors, and legal status can be corroborated by consulting the USPTO PAIR database or patent family records.
Key Takeaways
- U.S. Patent 11,191,766 covers specific formulations, manufacturing processes, and therapeutic uses of an active pharmaceutical ingredient.
- Claim scope balances broad protection of the active compound and narrow protection of particular embodiments or methods.
- The patent landscape features related patents from the same assignee and competitors, reflecting a crowded field.
- The patent provides strategic exclusivity but faces the usual challenges from prior art and potential validity disputes.
- Its enforceability will depend on how claims are interpreted in relation to prior art during potential litigation or patent office review.
FAQs
1. What is the main inventive element claimed in U.S. Patent 11,191,766?
It appears to be a specific formulation or manufacturing process involving a novel version of an active compound, likely improving stability, bioavailability, or ease of production.
2. How does this patent compare with prior related patents?
It likely builds on earlier patents by introducing new formulation nuances or synthesis methods. The scope aims to extend protected territories or therapeutic uses, filling gaps left by prior art.
3. Can this patent be challenged for validity?
Yes, through post-grant proceedings like inter partes review or patent litigation, based on prior art that predates its filing date.
4. Does the patent claim method or use broadly?
It claims both, with some broad independent claims covering the composition and specific method or use claims for targeted therapies.
5. How might this patent impact generic drug development?
It could delay generic entry if upheld and enforced, especially if broad claims cover the active ingredient or delivery method, but validity challenges remain possible.
References
[1] United States Patent and Trademark Office (USPTO). U.S. Patent 11,191,766.
[2] Patent landscape reports and related filings for the drug class.
[3] Prior art references cited during prosecution and in related patent families.
